Lorlatinib/lorlatinib drug related specifications

Lorlatinib is a targeted therapy drug that targets driver gene mutations and is mainly used to treat certain types of non-small cell lung cancer (NSCLC). Its clinical application is mainly for patients who have progressed after receiving other anti-cancer drugs. The mechanism of lorlatinib is to effectively block the proliferation and metastasis of tumor cells by inhibiting fusion genes and other related kinases.

The drug's molecular formula isC21H19FN6O2, which is somewhat complex. Its molecular weight is 406.41 Daltons, a characteristic that makes its metabolism and excretion in the body relatively unique. The structure of lorlatinib is designed to optimize its ability to bind to target kinases while improving the drug's bioavailability and tolerability. Lorlatinib is available in oral tablet form, with common dosage strengths of 25 mg and 100 mg. These tablets are suitable for daily use by adult patients and should be taken as directed by their doctor.

Lorlatinib can be taken once daily, before or after a meal, but to maintain consistent drug concentrations, it is recommended to take it at the same time. While patients are taking lorlatinib, they should undergo regular clinical follow-up, including imaging examinations and biochemical index monitoring, to evaluate the treatment effect and detect possible adverse reactions in a timely manner.

As a new type of small molecule targeted therapy drug, lorlatinib has relatively mild side effects. Common adverse reactions include fatigue, nausea, vomiting, diarrhea, loss of appetite, etc. In addition, lorlatinib may also cause more serious side effects such as neurological symptoms, including cognitive changes, mood swings, and peripheral neuropathy. Therefore, during the treatment process, doctors will make individual adjustments based on the patient's specific conditions to ensure the safety and effectiveness of the treatment.